Time modeling dependent biodistribution of holmium -166-DOTA-bevecizumab in human by compartment analysis

International Conference on Medical Physics

August 03-05, 2015 Birmingham, UK

A R Khorami Moghaddam, A Hakimi and A R Jalilian

Posters-Accepted Abstracts: J Nucl Med Radiat Ther

Abstract :

Introduction: The main aim of this study was to develop pharmacokinetic model for the colorectal cancer complex 166Ho- DOTA-bevacizumab in normal and tumoral rat to analyze of behavior as a new composition for diagnosis and treatment. The use of compartmental analysis allows a mathematical separation of tissues and organs to determine the concentration of activity in each fraction of interest. Biodistribution studies are expensive and difficult to carry out in humans, but such data can be obtained easily in rodents and rats. Materials & Methods: We have developed a physiologically based pharmacokinetic model for scaling up activity concentration in each organ vs. time. The mathematical model uses physiological parameters including organ volumes, blood flow rates, and vascular permeabilities. The compartments (organs) are connected anatomically. This allows the use of scale-up techniques to predict new complex distribution in humans in each organ. Results: The concentration of new complex was measured in various organs at different times. The behavior of the complex ( 166Ho-DOTA-bevacizumab) was modeled as a function of time in various organs. This data was diagramed as a time function in separated graph for each organ between 2-96 hours after injection. Conclusion: The variation of integrated uptake in organs is described with summation of 8-10 exponential terms and it approximated experimental data with 1-2 % precision.